Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,259 total articles

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
May 21, 2026
Marcus Reed
Press Releases

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) monotherapy in patients with relapsed or refractory systemic amyloid light chain (AL) amyloidosis. Lynozyfic demonstrated deep and rapid hematologic complete responses in all treated patients at the highest dose, with notable improvements in organ function…

REGN
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
Ajmal Hussain
Press Releases

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Pharmaceuticals announced that four abstracts involving its FDA-approved menin inhibitor Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting. Key highlights include an oral presentation showing favorable outcomes in acute leukemia patients receiving revumenib post-hematopoietic stem cell transplantation a…

SNDX
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
May 21, 2026
Maya Rios
Press Releases

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Akari Therapeutics announced positive preclinical data demonstrating that their lead antibody drug conjugate (ADC), AKTX-101, synergizes with KRAS inhibitors (including adagrasib) to enhance cytotoxic activity against KRAS-mutated pancreatic cancer models. Unlike traditional ADCs, AKTX-101 uses a novel RNA spliceosome modulating payload (PH1) that …

AKTX
Navient declares second quarter common stock dividend
May 21, 2026
Marcus Reed
Press Releases

Navient declares second quarter common stock dividend

Navient Corporation declared a second quarter 2026 dividend of $0.16 per common share, payable on June 19, 2026, to shareholders of record as of June 5, 2026. The company continues to focus on responsible lending, refinancing options, and financial services through its Earnest business unit.

NAVI
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
May 21, 2026
Hana Yamamoto
Press Releases

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology announced a webcast on June 3, 2026, to discuss updated Phase 2 clinical trial data of Onvansertib, their PLK1 inhibitor drug candidate combined with standard-of-care treatments for first-line RAS-mutated metastatic colorectal cancer. Updated results show dose-dependent improvements in overall response rate and progression-free sur…

CRDF
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
Jordan Park
Press Releases

Legend Biotech Announces Presentations at ASCO 2026

Legend Biotech announced multiple presentations at the ASCO 2026 meeting, including preliminary Phase 1 results for LB2102, a DLL3-targeted CAR-T therapy showing early activity in solid tumors like small cell lung cancer. Additional data on CARVYKTI (ciltacabtagene autoleucel) reinforces its efficacy in multiple myeloma, supporting ongoing studies …

LEGN
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Hana Yamamoto
Press Releases

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Olema Oncology announced encouraging preliminary results from the Phase 1 clinical trial of OP-3136, a selective KAT6 inhibitor, showing tolerability and anti-tumor activity across multiple advanced solid tumors. The data support continued development of OP-3136 both as monotherapy and combined with current endocrine therapies in metastatic breast …

OLMA
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026
Derek Hwang
Press Releases

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics announced encouraging Phase 1 trial results of CTX-8371, a novel bispecific antibody targeting PD-1 and PD-L1, demonstrating deep and durable responses in patients with advanced malignancies resistant to prior immune checkpoint inhibitors. The drug showed clinical activity in triple-negative breast cancer, Hodgkin lymphoma, and…

CMPX
NVIDIA Announces Upcoming Events for Financial Community
May 21, 2026
Hana Yamamoto
Press Releases

NVIDIA Announces Upcoming Events for Financial Community

NVIDIA has announced its participation in two upcoming major financial community events: the TD Cowen 54th Annual Technology, Media, & Telecom Conference on May 28, 2026, and the BofA Global Technology Conference on June 4, 2026. The company will webcast these financial presentations live, providing investors and industry stakeholders with updates …

NVDA
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
Nina Shah
Press Releases

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Corporation announced a 17.3-month median overall survival in a Phase 2a trial of atebimetinib combined with chemotherapy in first-line metastatic pancreatic cancer patients. The treatment showed a tolerable safety profile with only chemotherapy-related Grade 3 or higher adverse events observed in 10% or more of patients. The company wi…

IMRX
TruGolf Reports First Quarter 2026 Results
May 21, 2026
Derek Hwang
Press Releases

TruGolf Reports First Quarter 2026 Results

TruGolf Holdings reported a modest revenue decline to $5.0 million in Q1 2026 compared to $5.2 million in Q1 2025, with a slight drop in golf simulator sales offset by increased software contracts. The company reduced its net loss to $1.4 million from $2.7 million in the prior year quarter, driven by lower operating expenses and interest costs. Tru…

TRUG
CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman
May 21, 2026
Avery Klein
Press Releases

CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice Chairman

CVB Financial Corp., a top-performing California-based bank holding company with over $20 billion in assets, announced a leadership transition following its annual meeting. George A. Borba Jr., a long-serving director and Vice Chairman, has been appointed Chairman of the Board, succeeding Hal W. Oswalt who transitions to Vice Chairman. The company …

CVBF
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
May 21, 2026
Hana Yamamoto
Press Releases

Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

Seer, Inc.'s Board of Directors has unanimously rejected the revised unsolicited acquisition proposal from the Radoff-JEC Group, citing significant undervaluation and failure to reflect Seer's long-term growth prospects. The Board determined that the offer does not represent the best interests of shareholders. Seer continues to emphasize its positi…

SEER
Hub Group Declares Quarterly Dividend
May 21, 2026
Priya Menon
Press Releases

Hub Group Declares Quarterly Dividend

Hub Group, Inc. declares a quarterly dividend of $0.125 per share for its Class A and Class B common stock, payable on June 17, 2026, supporting its annual dividend target of $0.50 per share. This move reflects the company’s commitment to returning value to shareholders within its strategic growth plan.

HUBG
Kadant Authorizes Share Repurchase
May 21, 2026
Nina Shah
Press Releases

Kadant Authorizes Share Repurchase

Kadant Inc. announced that its Board of Directors has authorized a share repurchase program allowing the company to buy back up to $50 million of its equity securities between May 2026 and May 2027. This authorization follows the expiration of a previous repurchase plan and aims to optimize capital structure and return value to shareholders.

KAI
Kadant Declares Cash Dividend
May 21, 2026
Jordan Park
Press Releases

Kadant Declares Cash Dividend

Kadant Inc., a global supplier of sustainable industrial processing technologies, declared a quarterly cash dividend of $0.36 per share payable on August 13, 2026. The dividend highlights Kadant's commitment to returning value to shareholders amid ongoing operational performance. Future dividends will be subject to board approval and contingent on …

KAI
Hub Group Receives Expected Deficiency Notice from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
May 21, 2026
Ajmal Hussain
Press Releases

Hub Group Receives Expected Deficiency Notice from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Hub Group, Inc. announced it received a deficiency notice from Nasdaq for failing to timely file its quarterly Form 10-Q for the period ended March 31, 2026. Nasdaq has given the company a 180-day grace period until September 14, 2026 to regain compliance. Hub Group is working to complete restatements of prior years' financial statements and file d…

HUBG
OFA Group Transitions to U.S. Domestic Issuer Status; Reaffirms United States as the Center of Its Growth Strategy
May 21, 2026
Maya Rios
Press Releases

OFA Group Transitions to U.S. Domestic Issuer Status; Reaffirms United States as the Center of Its Growth Strategy

OFA Group announced it has transitioned from a foreign private issuer to a US domestic issuer effective April 1, 2026, reflecting its operational, leadership, and revenue concentration in the United States. The company reaffirmed its strategic focus on US-based growth initiatives including capital allocation, its real-world asset tokenization platf…

OFAL
Genco Shipping & Trading Limited Files Investor Presentation and Urges Shareholders to Vote for the Company’s Highly Qualified Nominees and Reject Diana’s Inadequate Tender Offer
May 21, 2026
Maya Rios
Press Releases

Genco Shipping & Trading Limited Files Investor Presentation and Urges Shareholders to Vote for the Company’s Highly Qualified Nominees and Reject Diana’s Inadequate Tender Offer

Genco Shipping & Trading Limited has filed an investor presentation urging shareholders to vote for the re-election of its current highly qualified board members and to reject Diana Shipping's inadequate $23.50 tender offer and its nominated director slate. Genco highlights its strong dividend performance, superior governance, and comprehensive val…

GNK